Dermatology and Therapy最新文献

{"title":"Correction: Bridging the Gap in Chronic Prurigo Care: Evidence-Based Diagnostic and Therapeutic Recommendations from a Delphi Consensus Panel.","authors":"Pedro Mendes-Bastos, Inês Lobo, Gilberto Pires da Rosa, Rita Pimenta, Margarida Gonçalo","doi":"10.1007/s13555-026-01877-w","DOIUrl":"https://doi.org/10.1007/s13555-026-01877-w","url":null,"abstract":"","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148705606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adherence to CAL/BDP PAD-Cream Influences Treatment Effectiveness and Preference in Scalp Psoriasis Under Real-Life Conditions: Results from the Prospective, Multicenter, Observational PRO-SCALP Study.","authors":"Anthony Bewley, Andreas Pinter, José Luis López Estebaranz, Jordi Galván, Víctor Sapena, Volker Koscielny","doi":"10.1007/s13555-026-01884-x","DOIUrl":"https://doi.org/10.1007/s13555-026-01884-x","url":null,"abstract":"<p><strong>Introduction: </strong>Scalp psoriasis is often associated with poor adherence to topical therapy. A novel formulation of calcipotriol and betamethasone dipropionate based on polyaphron dispersion (CAL/BDP PAD-cream) showed improved outcomes and satisfaction in the PRO-SCALP study, particularly in patients with high adherence. We evaluated how adherence to CAL/BDP PAD-cream influences patients- and clinicians-reported outcomes and treatment preferences in mild-to-moderate scalp psoriasis under real-life conditions in Europe.</p><p><strong>Methods: </strong>PRO-SCALP patients reported their adherence level using a visual analogue scale (VAS). Outcomes were compared between low- and high-adherence subgroups.</p><p><strong>Results: </strong>Among 252 patients, 59.9% reported high adherence (VAS 80-100). Older patients and those with moderate disease reported high adherence (both p < 0.05). High-adherent patients reported higher scores in the Treatment Satisfaction Questionnaire for Medication Version 9, for Convenience of use (p = 0.0019) and Global Satisfaction (p = 0.0166) domains, and in the Psychosocial Effects of Scalp Psoriasis Questionnaire (p = 0.0004) at week 8. Both adherence subgroups showed significant reductions in the scalp Worst Itch Numeric Rating Scale (WI-NRS), scalp-modified Psoriasis Area and Severity Index (S-mPASI), and Scalpdex scores (all p < 0.0001 vs. baseline), although high-adherent patients achieved greater improvements in WI-NRS (p < 0.0001), S-mPASI (p = 0.0153), and the Scalpdex Symptoms domain (p = 0.001) than low-adherent. Each 10% increase in adherence corresponded to a 0.10- and 0.35-point reduction in S-mPASI and WI-NRS (both p < 0.05) at week 8. Scalp-Physician Global Assessment success rates were comparable in low- vs. high-adherence subgroups (65.0% vs. 70.5%; p = 0.3633). Sleep quality improved significantly in both subgroups (p < 0.0001). High adherence was associated with higher Patient Preference Questionnaire scores (p = 0.0012), better Cream Usability Scalp Psoriasis Questionnaire ratings (p = 0.0455) and greater product consumption (p < 0.0001), despite similar once-a-day usage.</p><p><strong>Conclusion: </strong>High adherence to CAL/BDP PAD-cream was associated with greater effectiveness, satisfaction, preference, and QoL. While patients with low adherence still benefited, maximizing adherence is key for optimal real-world outcomes in scalp psoriasis.</p><p><strong>Trial registration number: </strong>ClinicalTrials.gov identifier NCT05811234.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148700426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Comparative Data on Long-Term Efficacy of Biologics in Moderate-to-Severe AD: An Expert Perspective on Using Indirect Comparison Methodology.","authors":"Matthias Augustin, H Chih-Ho Hong, Tiago Torres, Naiem T Issa","doi":"10.1007/s13555-026-01880-1","DOIUrl":"10.1007/s13555-026-01880-1","url":null,"abstract":"","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148683686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spironolactone versus Bicalutamide for Female Pattern Hair Loss: A 24-Month Unicenter Retrospective Comparative Study of Effectiveness and Safety.","authors":"Rocío Gil-Redondo, Juan Jimenez-Cauhe, Adrián Imbernon-Moya, Diego Buendía-Castaño, Patricia Burgos Blasco, Borja Díaz-Guimaraens, Miguel Domínguez-Santas, Ángela Hermosa-Gelbard, David Saceda-Corralo, Sergio Vañó-Galván","doi":"10.1007/s13555-026-01879-8","DOIUrl":"https://doi.org/10.1007/s13555-026-01879-8","url":null,"abstract":"<p><strong>Introduction: </strong>Female pattern hair loss (FPHL) is a chronic, progressive condition that affects quality of life. Off-label systemic antiandrogens are increasingly used, but comparative data remain limited.</p><p><strong>Methods: </strong>To compare the effectiveness, safety, and healthcare resource utilization of spironolactone versus bicalutamide in FPHL over 24 months, we conducted a unicenter retrospective cohort study of women with FPHL treated between 2018 and 2022. The primary outcome was mean change in Sinclair grade from baseline to month 24. Secondary outcomes included ≥ 1 grade improvement, adverse events, and healthcare utilization. Linear and ordinal logistic regression models were adjusted for baseline severity.</p><p><strong>Results: </strong>A total of 187 women (median age 35 years, range 15-69 years) completed 24 months of follow-up. Both drugs produced significant Sinclair grade improvement (mean change -0.5, p < 0.001). Spironolactone (n = 128) was superior, with 54.4% achieving ≥ 1 grade improvement versus 37.3% with bicalutamide (n = 59) (p = 0.030). High-dose spironolactone (> 100 mg/day, median 130 mg/day) showed greater benefit than the maximum bicalutamide dose (50 mg/day). Adverse event rate was similar, but bicalutamide caused more laboratory abnormalities and required closer monitoring.</p><p><strong>Conclusions: </strong>Both drugs are effective systemic options. Spironolactone, particularly > 100 mg/day, demonstrated greater efficacy, comparable safety, and less monitoring, supporting its potential role as first-line systemic option.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148683810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and Tolerability of Low-Dose Micronized Isotretinoin in Patients with Severe Recalcitrant Nodular Facial Acne in India: a Real-World Retrospective Study Using Electronic Medical Records.","authors":"Byalakere S Chandrashekar, Maya Vedamurthy, Seetharamanjaneyulu Kolalapudi, Vijaya Bhaskar Mallela, Shahnaz Arsiwala, Anil Ganjoo, Abir Saraswat, Farida Modi, Sowmya C Sujatha, Satish Udare, Surajit Gorai, Mukesh Gabhane, Bhavesh Lalan, Gaurang Jani, Aditi Jain, Shruti Dharmadhikari, Chintan Khandhedia, Prashant Devkare, Amey Mane, Asif Shaikh, Suyog Mehta","doi":"10.1007/s13555-026-01841-8","DOIUrl":"10.1007/s13555-026-01841-8","url":null,"abstract":"<p><strong>Introduction: </strong>Severe recalcitrant nodular facial acne is a chronic inflammation with considerable psychosocial impact. Conventional oral isotretinoin is effective, but optimal absorption necessitates dietary compliance. Micronized formulations improve bioavailability and allow flexible dosing. This study evaluated the effectiveness and tolerability of low-dose micronized isotretinoin.</p><p><strong>Methods: </strong>This real-world, retrospective, multicenter, observational study analyzed aggregated and anonymized electronic medical records (EMRs) collected over approximately 12 months from patients aged ≥ 12 years with severe recalcitrant nodular facial acne who were treated with low-dose micronized isotretinoin for ≥ 8 weeks. The primary endpoint was improvement in acne severity [in terms of Investigator's Global Assessment (IGA) score] from baseline to 8 ± 2 weeks. Secondary endpoints included improvement at the end of treatment, investigator-graded response, and incidence of adverse events (AEs; serious AEs [SAEs]). Exploratory endpoints assessed patient-graded response and change in nodular/total lesion count.</p><p><strong>Results: </strong>Among 305 patients (86.89% adults; 13.11% adolescents), 59.67% had an IGA score of 3 and 40.33% had an IGA score of 4 at baseline. Post-treatment, the overall IGA score reduced significantly from 3.40 ± 0.49 at baseline to 2.11 ± 0.79 at 8 ± 2 weeks (37.94% reduction; p < 0.001), 1.30 ± 0.82 at 12 ± 2 weeks (61.76% reduction; p < 0.001), and 0.53 ± 0.73 at 16 ± 2 weeks (84.41% reduction; p < 0.001). By 16 ± 2 weeks, 91.81% patients were graded 'clear'/'almost clear' (IGA score ≤ 1), 67.87% had 'excellent' investigator-graded response, and 65.25% had 'very good' self-graded response. After 16 ± 2 weeks, significant reductions were observed in nodular lesion counts (from 7.06 ± 9.22 to 0.38 ± 1.29; 94.62% reduction; p < 0.001) and total lesions (from 32.25 ± 36.95 to 2.46 ± 4.63; 92.37% reduction; p < 0.001). Six (1.97%) patients experienced AEs; no SAE was observed.</p><p><strong>Conclusion: </strong>In this real-world EMR-based study, low-dose micronized isotretinoin was found to be clinically effective and well tolerated in patients with severe recalcitrant nodular facial acne, achieving rapid and sustained improvements in lesion counts and acne severity.</p><p><strong>Trial registration: </strong>Clinical Trials Registry-India, identifier CTRI/2024/07/070813.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148683759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment Persistence of Interleukin-17 Inhibitors and Factors Associated with Persistence in Patients with Psoriasis Vulgaris in Japan: Retrospective Database Study.","authors":"Yayoi Tada, Hideaki Kagitani, Shuichi Kimura, Naoto Tsujimoto, Kiyotaka Mochizuki","doi":"10.1007/s13555-026-01878-9","DOIUrl":"https://doi.org/10.1007/s13555-026-01878-9","url":null,"abstract":"<p><strong>Introduction: </strong>Psoriasis vulgaris (PsV) is a chronic, immune-mediated skin disorder that significantly impairs quality of life and often necessitates long-term systemic therapy, especially in moderate-to-severe cases. In Japan, biologic agents targeting interleukin-17 (IL-17) have become central to the management of PsV; however, real-world evidence on their long-term persistence and associated factors remains limited.</p><p><strong>Methods: </strong>This retrospective study utilized the Medical Data Vision database to evaluate treatment persistence of IL-17 inhibitors (ixekizumab, secukinumab, brodalumab, or bimekizumab) and factors associated with treatment persistence in Japanese patients with PsV. Patients aged ≥ 15 years with a confirmed diagnosis of PsV and at least one claim of an IL-17 inhibitor between February 2015 and October 2023 were included. Persistence rates of IL-17 inhibitors (including ixekizumab) and ixekizumab were analyzed using the Kaplan-Meier method. Cox proportional hazard regression models were also used to calculate hazard ratios for factors associated with the treatment persistence of IL-17 inhibitors and ixekizumab.</p><p><strong>Results: </strong>The persistence rates at 48 months among patients treated with IL-17 inhibitors (n = 2904) and ixekizumab (n = 1105) were 52.4% and 41.2%, respectively. Similar rates were observed for ixekizumab dosing Q2/Q2 (46.9%) and Q2/Q4 (48.1%). Gender was a factor influencing treatment persistence in the IL-17 inhibitor cohort; however, no such association was observed in the ixekizumab cohort. Prior biologic experience was associated with shorter persistence for both IL-17 inhibitors and ixekizumab. No other demographic or clinical factors showed a significant association. Following ixekizumab treatment, use of phototherapy, topical, and systemic therapies declined, suggesting a shift toward biologic monotherapy.</p><p><strong>Conclusions: </strong>These findings provide real-world evidence of the sustained use of IL-17 inhibitors in Japanese patients with PsV. Persistence showed no significant association with patient characteristics such as age, comorbidities, and concomitant medications.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148663589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Variable-Dose Versus Continuous-Dose Abrocitinib Treatment in Patients with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis.","authors":"Jonathan I Silverberg, Eric L Simpson, Saleem A Farooqui, Gary Chan, Pinaki Biswas, Erman Güler","doi":"10.1007/s13555-026-01778-y","DOIUrl":"10.1007/s13555-026-01778-y","url":null,"abstract":"<p><strong>Introduction: </strong>Signs and symptoms of atopic dermatitis (AD) can fluctuate over time, necessitating a flexible dosing treatment approach for long-term management. This study evaluated the long-term efficacy and safety of variable-dose abrocitinib treatment in patients with moderate-to-severe AD compared with continuous abrocitinib 200-mg dosing.</p><p><strong>Methods: </strong>Patients from phase 3 trials in the JADE clinical program were divided into a continuous abrocitinib 200-mg dose cohort or a variable-dose cohort that received abrocitinib 100 mg and 200 mg at different phases of the trial(s).</p><p><strong>Results: </strong>At week 48 of abrocitinib treatment, 82% and 69% attained 75% improvement from baseline in the Eczema Area and Severity Index in the continuous abrocitinib 200 mg (n = 941) and variable-dose (n = 90) cohorts, respectively, while 67% and 44% achieved a ≥ 4-point improvement from baseline in the Peak Pruritus Numerical Rating Scale (PP-NRS4) response. In the continuous abrocitinib 200 mg and variable-dose cohorts, respectively, 23% and 13% achieved complete skin clearance per the Investigator's Global Assessment score of 0, and 44% and 21% achieved a PP-NRS of 0/1 (profound itch control). Similar trends were observed for patient-reported outcomes. Incidence rates for serious adverse events-those leading to discontinuation, deaths, and serious infections-were numerically higher in the variable-dose cohort but numerically lower for malignancies (excluding nonmelanoma skin cancer, major adverse cardiovascular events, venous thromboembolism, thrombocytopenia, lymphopenia, and retinal detachment compared with the continuous abrocitinib 200 mg cohort.</p><p><strong>Conclusion: </strong>Thus, sustained long-term efficacy was observed with both continuous abrocitinib 200 mg and variable-dose abrocitinib, with no new safety signals. Treatment with continuous abrocitinib 200 mg was the more efficacious treatment regimen, but flexible dosing with abrocitinib may be a viable treatment approach depending on individual patient characteristics and needs. Video abstract available for this article.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov identifiers NCT03349060 (trial registration date: November 17, 2017); NCT03575871 (trial registration date: June 15, 2018); NCT03720470 (trial registration date: October 24, 2018); NCT03796676 (trial registration date: January 4, 2019); NCT03627767 (trial registration date: May 29, 2018); NCT04345367 (trial registration date: March 27, 2020); NCT03422822 (trial registration date: December 20, 2017). Video Abstract (mp4 2239 KB).</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"3923-3939"},"PeriodicalIF":4.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13493663/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147980977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Duration-Dependent Adverse Events of Systemic Glucocorticosteroids in Atopic Dermatitis: A Nationwide Claims Cohort Study.","authors":"Theresa Klinger, Katharina Müller, Ricarda Graf, Matthias Augustin, Kristina Hagenström","doi":"10.1007/s13555-026-01829-4","DOIUrl":"10.1007/s13555-026-01829-4","url":null,"abstract":"<p><strong>Introduction: </strong>Systemic glucocorticosteroids (SGCs) are recommended only for short-term treatment of atopic dermatitis (AD) because of their side effect profile. Nevertheless, prolonged and repeated use remains common in routine care. Evidence on whether treatment duration or cumulative dose is the main driver of adverse events is limited. Therefore, the aim of this study is to investigate the longitudinal association between SGC treatment duration and side effects in persons with AD and to compare its impact with cumulative dose.</p><p><strong>Methods: </strong>This was a retrospective cohort study based on German statutory health insurance data that included persons with AD initiating SGC therapy. Associations between SGC exposure and side effect were analyzed using logistic regression and adjusted time-dependent Cox models.</p><p><strong>Results: </strong>Longer treatment duration was associated with higher odds of multiple side effects, including osteoporosis (odds ratio [OR] 1.21-1.27). In time-dependent Cox models, each additional quarter of SGC therapy increased the hazard of mental disorders (hazard ratio [HR] 1.21; 95% confidence interval [CI] 1.10-1.32), gastritis/duodenitis (HR 1.07; 1.00-1.15), osteoporosis (HR 1.37; 1.23-1.52), hypertension (HR 1.26; 1.08-1.48), and diabetes mellitus (HR 1.35; 1.09-1.69).</p><p><strong>Conclusions: </strong>Prolonged SGC therapy is associated with increasing risks of multiple side effects, supporting guideline recommendations for short-term use only. Documented SGC treatment duration showed more consistent associations with side effects than cumulative dose.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"4067-4082"},"PeriodicalIF":4.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13493672/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148293062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology and Treatment Patterns of Stage III Resectable Melanoma Treated with Adjuvant Therapy: A Real-World Study Using the SNDS Database in France.","authors":"Sandrine Monestier, Sebastien Branchoux, Louis Chillotti, François-Emery Cotté, Clémentine Curioz, Mélanie Goguillot, Stève Bénard, Carine Bellera, Nicolas Meyer","doi":"10.1007/s13555-026-01813-y","DOIUrl":"10.1007/s13555-026-01813-y","url":null,"abstract":"<p><strong>Introduction: </strong>Before the advent of neoadjuvant immunotherapy (IO) in macroscopic disease, IO and targeted therapies were recommended as adjuvant therapies for the treatment of stage III resectable melanoma. However, real-world evidence on their use and outcomes remains limited. This study described treatment patterns and survival outcomes among patients with stage III resectable melanoma who received adjuvant therapy in France.</p><p><strong>Methods: </strong>This retrospective cohort study used data from the exhaustive French national health data system (SNDS) to identify adults initiating adjuvant nivolumab (NIVO), pembrolizumab (PEM), or dabrafenib-trametinib (DT) between January 1, 2019, and December 31, 2021. Patients were followed until December 31, 2023, or death. Exclusion criteria included prior metastatic disease, other active cancers, or prior use of study drugs. Outcomes included treatment patterns at recurrence, described using Sankey diagrams, and survival (recurrence-free survival [RFS], overall survival [OS]), assessed using a Kaplan-Meier estimator.</p><p><strong>Results: </strong>The study population consisted of 2612 patients with resected stage III melanoma initiating an adjuvant therapy. Of them, 1483 (56.8%) received NIVO, 635 (24.3%) had PEM, and 494 (18.9%) had DT. Median (Q1-Q3) age was 64.0 (52.0-73.0) years for NIVO, 64.0 (51.0-74.0) years for PEM, and 58.0 (46.0-70.0) years for DT. Median follow-up was 39.5 months for NIVO, 38.9 months for PEM, and 36.9 for DT. At 36 months, RFS (95% CI) was 50.7% (48.0%-53.2%) for NIVO, 52.7% (48.6-56.7%) for PEM, and 48.3% (43.7-52.7%) for DT. Finally, 36-month OS (95% CI) was 81.8% (79.7-83.8%) for NIVO, 82.3% (79.0-85.2%) for PEM, and 74.4% (70.1-78.2%) for DT. Immunotherapy represented 75% of therapies at recurrence among patients with adjuvant NIVO/PEM and 55% among patients with adjuvant DT.</p><p><strong>Conclusion: </strong>Immunotherapy is the cornerstone of adjuvant and recurrence treatment in stage III melanoma, representing the vast majority of adjuvant therapies and recurrence therapies. Despite effective therapies, recurrence remains frequent, with around half of relapses at 3 years, underscoring the need for continued optimization of treatment strategies.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"3941-3960"},"PeriodicalIF":4.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13493711/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148204549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Modalities of Combined Medical and Surgical Treatment in Hidradenitis Suppurativa: A Systematic Review of Efficacy and Safety.","authors":"Laura Mateu-Arrom, Alejandro Molina-Leyva, Eva Vilarrasa","doi":"10.1007/s13555-026-01836-5","DOIUrl":"10.1007/s13555-026-01836-5","url":null,"abstract":"<p><p>Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by recurrent nodules, abscesses, and sinus tracts that lead to significant morbidity and impaired quality of life. Although both biologic therapies and surgical interventions are effective when used independently, their combined use has gained increasing attention. This systematic review aimed to evaluate the efficacy and safety of combining immunomodulatory therapy with surgical procedures in HS. A conceptual framework was applied that distinguished three modalities of combined treatment according to the temporal relationship between biologic therapy and surgery: pre-biologic surgery, post-induction surgery, and concomitant approaches. A comprehensive search identified eight eligible studies, including 508 patients. Most studies were retrospective and of low methodological quality. Across studies, combination therapy (particularly with adalimumab, secukinumab, or bimekizumab) was generally associated with improved clinical outcomes compared to biologic monotherapy, including higher response rates (Hidradenitis Suppurativa Clinical Response [HiSCR]; 55% reduction in the International Hidradenitis Suppurativa 4 [IHS4-55]), greater reductions in pain, disease flares, and Dermatology Life Quality Index scores. Safety profiles were comparable between groups, with no consistent increase in postoperative complications or serious adverse events. However, key outcomes such as wound healing time were poorly reported. Substantial heterogeneity in study design, treatment protocols, and timing of interventions limited comparability and precluded meta-analysis. Overall, the available evidence preliminarily supports combined medical and surgical treatment as a potentially beneficial and well-tolerated strategy for moderate-to-severe HS, in line with current expert practice. However, given the low quality and substantial heterogeneity of the included studies, these findings should be considered exploratory and require confirmation in higher-quality prospective studies that adopt standardized definitions of combination therapy and report wound healing as a core outcome.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"3813-3829"},"PeriodicalIF":4.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13493712/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148301172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}